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Clinical case
Pharmacological management of inappropriate sexual behaviors in youth
with autism spectrum disorder: A case study and review of the literature
Traitement médicamenteux de comportements sexuels inappropriés chez les jeunes atteints d’un
trouble de l’autisme : un cas clinique et revue de la littérature
F. Chen ∗, C. Grandjean , S. Richard
Département de psychiatrie, service de psychiatrie pour enfants et adolescents (SPEA), secteur psychiatrique Nord (SPN), centre hospitalier universitaire Vaudois
(CHUV), 12, rue du Valentin, 1400 Yverdon-les-Bains, Switzerland
bstract
Inappropriate sexual behaviors are common in children and youth with autism spectrum disorder that could lead to major distress in the patient
nd caregivers and sometimes could lead to the patient’s expulsion from a social environment. When educational and behavioral intervention failed
n reducing such behaviors, pharmacological management would be necessary. We presented here a clinical vignette of treatment of inappropriate
exual behaviors in an adolescent boy with autistic disorder. We further made a review of the literature on its pharmacological management. Our
eview revealed very limited documentation with only some cases studies that have reported successful treatment by several medications. More
ontrolled studies are needed.
 2016 Elsevier Masson SAS. All rights reserved.
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ésumé
Les comportements sexuels inappropriés sont fréquents chez les jeunes atteints d’un trouble de l’autisme. Ce type de comportement socialement
nacceptable peut entraîner des rejets sociaux et des grandes souffrances chez le patient et sa famille. Malgré des mesures éducatives et des
nterventions comportementales, un traitement médicamenteux est parfois nécessaire pour mieux gérer ce type de comportement. Nous présentons
ci un cas clinique et une revue de littérature sur le traitement médicamenteux de comportements sexuels inappropriés chez les jeunes atteints d’un
rouble de l’autisme.
 2016 Elsevier Masson SAS. Tous droits réservés.
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.  Introduction
Autism spectrum disorder (ASD) is characterized by per-
istent deficits in social interaction and social communication
cross multiple contexts, as well as restricted and repetitive
atterns of behavior, interests or activities [1]. Despite of the
ncommon developmental trajectories, many individuals with
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utism demonstrate their interest in discovering sexuality [2,3]
nd desire relationships, as their peers with a typical develop-
ent do. It seems important to accept sexuality as a normative
art of adolescent development in youth with ASD who may suf-
er from particular difficulties on learning and daily functioning
elating to sexuality [4]. Studies examining children and younger
dolescents with ASD demonstrate that they may have less sex
ducation and poorer knowledge regarding privacy issues and
isplay more inappropriate sexual behaviors [2] mostly due to
 poorer social ability and lack of effective sexual education.
hildren with autism may require intensive social and sexual
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ducation interventions starting at a very young age [5]. How-
ver, even pediatricians who were aware of such importance
ound it difficult to address sexuality-related issues in children
nd youth with ASD especially topics about prevention of sex-
al abuse and inappropriate sexual behaviors [6]. Previously
eported inappropriate sexual behaviors in children and youth
ith ASD include undressing or masturbating in public, exces-
ive masturbation, touching other people’s private body area and
exual fetishism. One of the primary parental concerns relat-
ng to sexuality is the vulnerability of their child with ASD to
nvolvement in sexual risk taking and negative sexual behaviors
utcomes (being sexually abused or demonstrating behaviors
hat can be misregarded as sexually provocative) [7]. To prevent
nd treat socially unacceptable sexual behaviors, psychoeduca-
ion programs and behavior therapy have often been proposed as
rst-line intervention and have demonstrated their efficacy [8].
hen educational and behavioral intervention failed in reducing
uch target behaviors, pharmacological management would be
ecessary. To date, however, still little is known about the use
f medication to treat inappropriate sexual behaviors in children
nd young adults, especially in those with ASD.
Here, we presented a clinical vignette of treatment of inap-
ropriate sexual behaviors in a 14-year-old adolescent boy with
utistic disorder. We further made a review of the literature to
xpand our knowledge about pharmacological management of
nappropriate sexual behaviors in youth with ASD.
.  Clinical  vignette
Samuel1 is a 14-year-old male adolescent with autism with
 normal IQ. The early warning signs of autism have been
bserved at nursery: he had poor eye contact and attention deficit;
e rarely spoke to others or used only echolalia; he seemed to
e in his own world and failed to initiate or respond to social
nteractions with his pairs; he didn’t have pretend play. He was
hen integrated in a special class and benefited a lot from a
peech-language therapy. Samuel later acquired a better level
f language and showed a preserved cognitive ability. When
e was 9, risperidone (Risperdal®) 0.5 mg/day was adminis-
ered to manage his aggression and self-injurious behaviors
elated to his social-communicating difficulties. These behav-
oral problems quickly diminished. However, risperidone led
o a progressive but important weight gain in spite of dietetic
ounseling. When he was 12, risperidone was replaced by arip-
prazole (Abilify®) 10 mg/day. The weight gain stagnated while
amuel began complaining of persisting tiredness and headache.
is parents reported daytime erection and think it could be a side
ffect of the medication. Aripiprazole was then progressively
topped and replaced later by amisulpride (Solian®).
Samuel’s hypersexual behaviors appeared about 2 years ago
ith the onset of puberty. He was once excluded from a sportlub after having touched provocatively the breast of a girl in
rder to show his discontent to the monitor. He was reported
o have excessive open masturbation at home, which was very
1 All the identifying details have been changed.
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mbarrassing for other family members. More recently, a
eenager girl accused Samuel to have forced her to be touched
nd suced on her private part in toilet. Samuel seemed to be con-
used and hurt, asking why the girl who accepted his kiss would
ccuse him for sexual caress. For him, they were already a couple
fter the kiss and a couple should have sexual relationship. After
his event, Samuel became very anxious and showed depressed
ood with suicidal threat. He was hospitalized during 4 weeks in
 child and adolescent psychiatric inpatient unit. The daily dose
f his treatment by amisulpride was then increased to 300 mg.
is anxiodepressive symptoms rapidly diminished and he didn’t
how any inappropriate sexual behavior during the hospitaliza-
ion. He was now back to school and waiting for an evaluation
nd guidance on sexuality prescribed by the Juvenile Court. A
esidential treating center specialized for individuals with autism
ould be very helpful to offer him psychoeducation programs
nd behavior therapy on sexuality. Unfortunately, only very
imited places exist in the French-speaking part of Switzerland.
In this clinical vignette, the patient presented 3 types of
hallenging behaviors. The first one seems to be a kind of impul-
ive provocative behavior with less sexual intention. Samuel
xplained that he touched the breast of the girl in the swim-
ing pool although he knew it’s forbidden. He did it anyway
o show that he was angry at the monitor. Undoubtedly, this
ehavior was perceived by others as with clear sexual inten-
ion while it was not the case for Samuel. The second type of
nappropriate sexual behaviors is his excessive open masturba-
ions at home which should be nuanced, in our opinion, in the
ight of normal adolescent sexuality development. Samuel has
ever been reported to masturbate outside his home; however, it
eems to be still difficult for him to understand that “at home”
s not equal to “private”. The third type of inappropriate sexual
ehaviors for which he has been accused was with clear sexual
ntention while based on some romantic feelings. Apparently,
amuel didn’t understand that more intimate approach without
onsent would be perceived as sexual offending. Due to their
ore social deficits, individuals with ASD may be naive about
otential consequences of their social-rule-breaking-behaviors.
.  Review  of  the  literature
In order to expand our knowledge about pharmacological
anagement of inappropriate sexual behaviors in children and
outh with ASD, we further reviewed related publications via
edline (http://www.ncbi.nlm.nih.gov/pubmed). Only English
ublications were included, covering children and young adults
ged up to 24 years (as defined by United Nations the term
youth”). We have chosen especially reports describing pharma-
ological agents other than antipsychotics that have been widely
sed in individuals with ASD.
As shown in Table 1, the literature on pharmacological
reatment of inappropriate sexual behaviors in children and
outh with ASD seems to be very limited. Medline search
evealed only several case reports, including 6 single-case
eports [5,9–13] and 1 case-series [14].
Successful suppression of inappropriate sexual behaviours
as been reported in a 24-year male with ASD [5], using
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Table 1
Case reports of pharmacological treatment of inappropriate sexual behaviors in youth with ASD.
Author Treatment Subjects (age) Target symptoms Effective dosage
Realmuto and Ruble (1999) [5] Leuprolide (injectable) 1 male, 24 years Persistent public
masturbation
7.5 mg/month
(then switched
slowly to a
maintenance dose
of 1.87 mg/month)
Jones and Okere (2008) [9] Estrogen (oral) 1 male, 23 years Hypersexual behavior,
toward female strangers
with masturbation and
penile discharge
0.625 mg/day
Nguyen and Murphy (2001) [10] Mirtazapine (oral) 1 male, 13 years Excessive masturbation
with public display
45 mg/day
Albertini et al. (2006) [11] Mirtazapine (oral) 1 male, 5 years Compulsive public
masturbation
5 mg/day
Coskun and Mukaddes (2008) [12] Mirtazapine (oral) 1 male, 13 years Fetishism and public
inappropriate sexual
behaviors
15 mg/day
Coskun et al. (2009) [14] Mirtazapine (oral) 8 males and
1 female aged
5.2–16.4 years
Excessive masturbation,
fetishism and public
inappropriate sexual
behaviors
7.5–30 mg/day
Deepmala and Agrawal (2014) [13] Propranolol (oral) 1 male, 13 years Public display of
inappropriate sexual
0.3 mg/kg/day
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anjectable leuprolide that could reduce testosterone level by
cting as an agonist at pituitary GnRH receptors. While flu-
amide, an anti-androgen has not been effective in this patient.
ral estrogen has been applied in a 23-year male with ASD
9] leading to a significant reduction in his hypersexual behav-
or. Albertini et al. [11] reported an effective daily dosage of
 mg of mirtazapine in treating compulsive public masturba-
ion in a 5-year boy with ASD. Nguyen and Murphy [10]
eported beneficial effects of mirtazapine with a daily dose
f 45 mg in minimizing hypersexual behaviors in a 13-year
oy with ASD, while Coskun and Mukaddes [12] reported a
uccessful suppression of fetishism and public inappropriate
exual behaviors with a daily dose of only 15 mg of mir-
azapine in an autistic boy of the same age. Coskun et al.
14] confirmed the efficacy of mirtazapine in treating exces-
ive masturbation, fetishism and public inappropriate sexual
ehaviors in a case-series of 9 children and adolescents with
SD. A more recent case study [13] reported a low-dose trial
f propranolol (0.3 mg/kg/day) leading to significant improve-
ent in hypersexual behaviors in a 13-year adolescent with
SD.
.  General  discussion
Inappropriate sexual behaviors are common in children and
outh with ASD who are known to have particular difficulties
on learning and daily functioning relating to sexuality” [4,15].
hese socially unacceptable behaviors could lead to major dis-ress in the patient and caregivers and sometimes could lead
o the patient’s expulsion from a social environment [13], as
hat happened to Samuel in our case presentation. Children and
oung adults with ASD have the right, and need to learn how, to
y
obehaviors
xpress their sexual impulses and to manage their sexual needs
n a socially acceptable way [16].
When educational and behavioral intervention failed in
educing such behaviors, pharmacological management would
e necessary. Our review revealed that the literature on phar-
acological treatment of such behaviors especially in children
nd youth with ASD is very limited. In our opinion, the limited
se of pharmacological management of inappropriate sexual
ehaviors is mainly due to the complex nature of such behav-
ors in children and youth with ASD who suffer from their
isabilities in expressing the desire of relationship, in discov-
ring the sexuality and in establishing a sexual identity. As
as been pointed out by Realmuto and Ruble [5], there are
till many “unanswered clinical, ethical and legal dilemmas for
reatment of sexual deviance in individuals with developmental
isability”. Although the anti-androgenic medications (leupro-
ide, flutamide, estrogen, medroxyprogesterone acetate [MPA],
yproterone acetate [CPA, Androcur®]) were commonly used
n adult sex offenders, one could hardly apply them as first-
ine choice in younger patients with ASD, for ethical reason.
n non-autistic adolescents with and without mental retardation,
PA has been reported to be an efficient treatment of sexually
eviant behaviors [17,18]. Liver toxicity has been recognized
s a complication of long-term use of CPA [19]. Testosterone
uppression may also lead to osteoporosis. Caution is especially
arranted in children and young adolescents because the effects
f hormonal agents on the normal growth and development of
outh are not known [20]. The American academy of child
nd adolescent psychiatry (AACAP) discouraged their use with
outh under the age of 17 [21].
Atypical antipsychotics have also been used to treat adult sex
ffenders since sexual dysfunction is a common side effect in
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atients treated with antipsychotics. However, hyper-sexuality
ould also appear as side effect of antipsychotics, which has
een reported in adults taking aripiprazole [22] and in pediatric
atients treated with olanzapine [23]. In individuals with autism,
he antipsychotic drugs are among the most commonly used
sychopharmacological agents for the treatment of challenging
ehaviors (aggression toward others, self-injury, etc). It is thus
mportant to evaluate firstly the contribution of actual antipsy-
hotic medication to the target inappropriate sexual behaviors
efore increasing the dose of the antipsychotics or applying
ther medication. In our case study, the administration of another
typical antipsychotic successfully helped the patient to better
ontrol his impulsive sexual thoughts and behaviors and it has
ot been necessary to use other more specific medication to
reat the target behavior. Samuel’s daytime erection was reported
oincidentally after the administration of aripiprazole. It has
een suggested that antipsychotics causing higher serotonin and
ess dopamine blockade may have more risk of drug-related
yper-sexuality [23]. Drug-induced hyperprolactinemia has also
een hypothesized to be responsible for secondary sexual
ysfunctions observed in patients treated by antipsychotic med-
cations. Some second-generation antipsychotics are considered
s “prolactin-raising” (especially amisulpride, risperidone and
aliperidone which were associated with the highest hyperpro-
actinemia) while other second-generation antipsychotics are
onsidered as “prolactin-sparing” (especially aripiprazole often
ssociated with decreased prolactin level) or neutral (clozap-
ne, quetiapine) [24]. However, the evidence for an association
etween prolactin elevation and sexual side effects seems to be
till contradictory and inconclusive [24]. In our patient Samuel,
nfortunately, the prolactinemia has not been measured. We
now only that he didn’t develop a gynecomastia but we don’t
now whether his positive evolution was due to a potential drug-
nduced hyperprolactinemia.
Selective serotonin reuptake inhibitors (SSRIs) have also
een used to treat hyper-sexuality not only because inappropriate
exual behaviors are often considered as compulsive in nature
ut also because serotonin is considered as the main inhibitory
eurotransmitter of sexual response [25]. However, SSRIs has
een reported to worsen the level of irritability and to have
ther behavioral side effects including “restless, hyperactivity,
xcessive activation” leading to discontinuation of the treatment
10]. Mirtazapine is an antidepressant with potent 2-adrenergic
ntagonism, resulting in an increase of both noradrenergic and
erotoninergic neurotransmission [26]. Its reported efficacy in
reating inappropriate sexual behaviors seems to be associated
o its serotonergic activity [10]. The known side effects of mir-
azapine are sedation and weight gain, which should be taken
nto consideration when making treatment choices in children
nd adolescents. In our case study, the important overweight of
he patient made mirtazapine difficult to be a first-line choice.
Propranolol is a widely-used beta-blocker and “may poten-
ially impact on sexual functioning through a variety of
echanisms, including a reduction in central sympathetic out-
ow, impairment of vasodilation of the corpora cavernosa,
ffects on luteinizing hormone and testosterone secretion and
 tendency to produce sedation or depression, thereby causing a
[ et de l’adolescence 64 (2016) 163–167
oss of libido” [27]. It’s a FDA approved treatment for children
ith hypertension and arrhythmia and is considered safe and
enerally well tolerated in children. The above-mentioned suc-
essful low-dose propranolol trial for minimizing hypersexual
ehavior in an adolescent with ASD [13] offers a new therapeutic
ption.
.  Conclusion
Inappropriate sexual behaviors are common challenging
ehaviors in children and youth with autism. Psychoeduca-
ion programs and behavior therapy have demonstrated their
fficacy. Specialized institution is needed in order to promote
hese programs. The anti-androgenic medications are not recom-
ended as first-line choice in pediatric population and caution is
specially warranted because of their unknown effect on the chil-
ren’s growth and development. Some atypical antipsychotics
ould also be used to treat these socially unacceptable behaviors
hen educational and behavioral intervention failed in reducing
hem. Mirtazapine and propranolol provide interesting therapeu-
ic option, but the literature is still very limited. More controlled
tudies are needed.
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